tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement

TipRanks Clinical-Trials-Auto-Generated Newsdesk

TipRanks Reporter

TipRanks’s Recent Articles

AstraZeneca’s PROVIDENCE Study: Real-world Insights into Trastuzumab Deruxtecan for Metastatic Breast Cancer
AstraZeneca’s PROVIDENCE Study: Real-world Insights into Trastuzumab Deruxtecan for Metastatic Breast Cancer
AstraZeneca (($AZN)) announced an update on their ongoing clinical study. Study Overview: AstraZeneca is conducting a study titled...
24h ago
AZN
Regeneron’s Innovative Cancer Study: A Potential Game-Changer for Advanced Tumors
Regeneron’s Innovative Cancer Study: A Potential Game-Changer for Advanced Tumors
Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is conducting a clinical study...
24h ago
REGN
Regeneron Advances Melanoma Treatment with Long-term Study Update
Regeneron Advances Melanoma Treatment with Long-term Study Update
Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Study Overview: Regeneron Pharmaceuticals is conducting a...
24h ago
REGN
Regeneron’s Latest Clinical Study on Advanced NSCLC: A Potential Game Changer?
Regeneron’s Latest Clinical Study on Advanced NSCLC: A Potential Game Changer?
Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is conducting a clinical study...
24h ago
REGN
Sanofi’s Promising Ulcerative Colitis Study: What Investors Need to Know
Sanofi’s Promising Ulcerative Colitis Study: What Investors Need to Know
Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi is conducting a clinical study titled ‘A...
24h ago
SNYNF
Celldex Therapeutics Advances in Prurigo Nodularis Treatment with Barzolvolimab Study
Celldex Therapeutics Advances in Prurigo Nodularis Treatment with Barzolvolimab Study
Celldex Therapeutics (($CLDX)) announced an update on their ongoing clinical study. Study Overview: Celldex Therapeutics is conducting a...
1d ago
CLDX
AstraZeneca’s Promising Phase II Study on AZD0901 for Advanced Solid Tumors
AstraZeneca’s Promising Phase II Study on AZD0901 for Advanced Solid Tumors
AstraZeneca (($AZN)) announced an update on their ongoing clinical study. AstraZeneca is currently conducting a Phase II clinical...
1d ago
AZN
AstraZeneca’s Latest Phase 4 Study: A Boost for HER2-Positive Breast Cancer Treatment?
AstraZeneca’s Latest Phase 4 Study: A Boost for HER2-Positive Breast Cancer Treatment?
AstraZeneca (($AZN)) announced an update on their ongoing clinical study. Study Overview: AstraZeneca is conducting a Phase 4...
1d ago
AZN
AstraZeneca’s Tezepelumab Study: A Potential Game-Changer for COPD Treatment
AstraZeneca’s Tezepelumab Study: A Potential Game-Changer for COPD Treatment
AstraZeneca (($AZN)) announced an update on their ongoing clinical study. AstraZeneca, in collaboration with Amgen, is conducting a...
1d ago
AZN
Eli Lilly’s New Study on LY3537031: A Potential Game-Changer in Weight Management?
Eli Lilly’s New Study on LY3537031: A Potential Game-Changer in Weight Management?
Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Eli Lilly and Company is...
1d ago
LLY
OSE Immunotherapeutics Advances Phase 3 Trial for NSCLC Vaccine
OSE Immunotherapeutics Advances Phase 3 Trial for NSCLC Vaccine
OSE Immunotherapeutics (($DE:6OP)) announced an update on their ongoing clinical study. OSE Immunotherapeutics is conducting a pivotal Phase...
1d ago
6OP
Eli Lilly’s New Phase 1 Study: A Potential Game Changer?
Eli Lilly’s New Phase 1 Study: A Potential Game Changer?
Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Eli Lilly and Company is...
1d ago
LLY
AstraZeneca and AbbVie: New Phase II Study Targets Relapsed CLL/SLL
AstraZeneca and AbbVie: New Phase II Study Targets Relapsed CLL/SLL
AstraZeneca (($AZN)), Abbvie (($ABBV)) announced an update on their ongoing clinical study. Study Overview: The MAVRiC Study, officially...
1d ago
AZN
ABBV
Regeneron’s Promising NSCLC Study: A Game Changer in Cancer Treatment?
Regeneron’s Promising NSCLC Study: A Game Changer in Cancer Treatment?
Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is currently conducting a study...
1d ago
REGN
Sanofi’s Promising Crohn’s Disease Study: What Investors Need to Know
Sanofi’s Promising Crohn’s Disease Study: What Investors Need to Know
Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Study Overview: Sanofi is conducting a Phase 2...
1d ago
SNYNF
AbbVie’s ABBV-525 Study: A Potential Game-Changer in B-Cell Malignancies
AbbVie’s ABBV-525 Study: A Potential Game-Changer in B-Cell Malignancies
Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie is conducting a first-in-human study titled ‘A...
1d ago
ABBV
Gilead Sciences Advances GS-4321 Study for Chronic Hepatitis Delta
Gilead Sciences Advances GS-4321 Study for Chronic Hepatitis Delta
Gilead Sciences (($GILD)) announced an update on their ongoing clinical study. Gilead Sciences is currently conducting a clinical...
1d ago
GILD
Avidity Biosciences’ Promising Phase 3 Study on Del-desiran for DM1: What Investors Need to Know
Avidity Biosciences’ Promising Phase 3 Study on Del-desiran for DM1: What Investors Need to Know
Avidity Biosciences Inc (($RNA)) announced an update on their ongoing clinical study. Study Overview: Avidity Biosciences Inc. is...
1d ago
RNA
Eli Lilly’s Gene Therapy Trial: A Potential Breakthrough in Hearing Loss Treatment
Eli Lilly’s Gene Therapy Trial: A Potential Breakthrough in Hearing Loss Treatment
Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: The clinical trial...
1d ago
LLY
Sanofi’s Amlitelimab Study: A Potential Game-Changer for Atopic Dermatitis
Sanofi’s Amlitelimab Study: A Potential Game-Changer for Atopic Dermatitis
Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi is conducting a long-term extension study titled...
1d ago
SNYNF
AstraZeneca’s Tezepelumab Study: A Potential Game-Changer for COPD Treatment
AstraZeneca’s Tezepelumab Study: A Potential Game-Changer for COPD Treatment
AstraZeneca (($AZN)) announced an update on their ongoing clinical study. AstraZeneca, in collaboration with Amgen, is conducting a...
1d ago
AZN
EXACT Therapeutics’ Promising Pancreatic Cancer Study: A Closer Look
EXACT Therapeutics’ Promising Pancreatic Cancer Study: A Closer Look
EXACT Therapeutics AS (($DE:56F)) announced an update on their ongoing clinical study. EXACT Therapeutics AS is conducting a...
1d ago
56F
Gilead Sciences Advances Pediatric HIV Treatment with New Study Update
Gilead Sciences Advances Pediatric HIV Treatment with New Study Update
Gilead Sciences (($GILD)) announced an update on their ongoing clinical study. Gilead Sciences is conducting a Phase 2/3...
1d ago
GILD
AbbVie’s Promising Phase 2 Study on ABBV-932 for Anxiety Disorder
AbbVie’s Promising Phase 2 Study on ABBV-932 for Anxiety Disorder
Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 2 study titled...
1d ago
ABBV
Gilead Sciences Advances Endometrial Cancer Treatment with New Phase 3 Study
Gilead Sciences Advances Endometrial Cancer Treatment with New Phase 3 Study
Gilead Sciences (($GILD)) announced an update on their ongoing clinical study. Study Overview: Gilead Sciences is conducting a...
1d ago
GILD
Regeneron and Intellia’s Phase 3 Study on NTLA-2001: A Potential Game-Changer for Genetic Disorders
Regeneron and Intellia’s Phase 3 Study on NTLA-2001: A Potential Game-Changer for Genetic Disorders
Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Study Overview: The MAGNITUDE-2 study, officially titled...
1d ago
REGN
AstraZeneca’s Latest Study: Insights into Metastatic Breast Cancer Treatment
AstraZeneca’s Latest Study: Insights into Metastatic Breast Cancer Treatment
AstraZeneca (($AZN)) announced an update on their ongoing clinical study. Study Overview: AstraZeneca is conducting a study titled...
1d ago
AZN
AbbVie’s Promising Study on ABBV-706 for Small Cell Lung Cancer
AbbVie’s Promising Study on ABBV-706 for Small Cell Lung Cancer
Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie is conducting a significant clinical study titled...
1d ago
ABBV
AbbVie’s New Study on Telisotuzumab Adizutecan: Potential Game-Changer for NSCLC?
AbbVie’s New Study on Telisotuzumab Adizutecan: Potential Game-Changer for NSCLC?
Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie is conducting a clinical study titled Phase...
1d ago
ABBV
Exelixis Advances Phase 1 Study of XL309 for Advanced Solid Tumors
Exelixis Advances Phase 1 Study of XL309 for Advanced Solid Tumors
Exelixis (($EXEL)) announced an update on their ongoing clinical study. Exelixis is currently conducting a Phase 1 clinical...
1d ago
EXEL
Eli Lilly’s Promising Parkinson’s Study: A Closer Look at LY4006896
Eli Lilly’s Promising Parkinson’s Study: A Closer Look at LY4006896
Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and...
1d ago
LLY
Eli Lilly’s New Study on LY3867070: What Investors Need to Know
Eli Lilly’s New Study on LY3867070: What Investors Need to Know
Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and...
1d ago
LLY
Actinium Pharmaceuticals’ New AML Treatment Study: A Potential Game Changer
Actinium Pharmaceuticals’ New AML Treatment Study: A Potential Game Changer
Actinium Pharmaceuticals (($ATNM)) announced an update on their ongoing clinical study. Study Overview: Actinium Pharmaceuticals is conducting a...
1d ago
ATNM
AstraZeneca’s ALXN1920 Study: A New Hope for Kidney Disease Treatment?
AstraZeneca’s ALXN1920 Study: A New Hope for Kidney Disease Treatment?
AstraZeneca (($AZN)) announced an update on their ongoing clinical study. AstraZeneca, in collaboration with Alexion Pharmaceuticals, is conducting...
1d ago
AZN
Regeneron’s Phase 2 Melanoma Study: A Potential Game-Changer in Cancer Treatment
Regeneron’s Phase 2 Melanoma Study: A Potential Game-Changer in Cancer Treatment
Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is conducting a Phase 2...
1d ago
REGN
Coloplast’s Innovative Heylo™ Study: A Game Changer in Stoma Care?
Coloplast’s Innovative Heylo™ Study: A Game Changer in Stoma Care?
Coloplast A/S (($GB:0QBO)) announced an update on their ongoing clinical study. Coloplast A/S is conducting a Prospective Longitudinal...
1d ago
0QBO
AstraZeneca’s AZD9793 Study: A New Frontier in Cancer Treatment
AstraZeneca’s AZD9793 Study: A New Frontier in Cancer Treatment
AstraZeneca (($AZN)) announced an update on their ongoing clinical study. AstraZeneca is conducting a study titled ‘A Modular...
1d ago
AZN
Annovis Bio’s Promising Alzheimer’s Study: What Investors Need to Know
Annovis Bio’s Promising Alzheimer’s Study: What Investors Need to Know
Annovis Bio Inc (($ANVS)) announced an update on their ongoing clinical study. Annovis Bio Inc. is conducting a...
1d ago
ANVS
AstraZeneca’s Promising Phase II Study for Liver Cancer Treatment
AstraZeneca’s Promising Phase II Study for Liver Cancer Treatment
AstraZeneca (($AZN)) announced an update on their ongoing clinical study. AstraZeneca is conducting a Phase II clinical study...
1d ago
AZN
Argenx’s Phase 3 Study on Efgartigimod: A Potential Game-Changer in Autoimmune Treatment
Argenx’s Phase 3 Study on Efgartigimod: A Potential Game-Changer in Autoimmune Treatment
Argenx (($ARGX)) announced an update on their ongoing clinical study. Argenx is conducting a Phase 3 clinical study...
1d ago
ARGX
Cerus Corporation’s New Study on Pathogen-Reduced RBCs: A Potential Game-Changer for Sickle Cell Disease
Cerus Corporation’s New Study on Pathogen-Reduced RBCs: A Potential Game-Changer for Sickle Cell Disease
Cerus Corporation (($CERS)) announced an update on their ongoing clinical study. Study Overview: Cerus Corporation is conducting a...
1d ago
CERS
Intuitive Surgical’s Robotic Mastectomy Study: A Potential Game-Changer
Intuitive Surgical’s Robotic Mastectomy Study: A Potential Game-Changer
Intuitive Surgical (($ISRG)) announced an update on their ongoing clinical study. Study Overview: Intuitive Surgical is conducting a...
1d ago
ISRG
Regeneron’s Linvoseltamab: A Promising Study for High-Risk Multiple Myeloma
Regeneron’s Linvoseltamab: A Promising Study for High-Risk Multiple Myeloma
Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is conducting a Phase 2...
1d ago
REGN
Alnylam’s TRITON-CM Study: A Potential Breakthrough in Cardiomyopathy Treatment
Alnylam’s TRITON-CM Study: A Potential Breakthrough in Cardiomyopathy Treatment
Alnylam Pharmaceuticals (($ALNY)) announced an update on their ongoing clinical study. Alnylam Pharmaceuticals is conducting a Phase 3...
1d ago
ALNY
Ipsen’s Odevixibat Study: A Potential Game-Changer for Alagille Syndrome
Ipsen’s Odevixibat Study: A Potential Game-Changer for Alagille Syndrome
Ipsen (($GB:0MH6)) announced an update on their ongoing clinical study. In a recent update, Ipsen is conducting a...
1d ago
0MH6
ICON Plc and Zealand Pharma’s Petrelintide Study: A Key Update for Investors
ICON Plc and Zealand Pharma’s Petrelintide Study: A Key Update for Investors
Icon Plc (($ICLR)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled ‘Pharmacokinetics...
1d ago
ICLR
Coloplast A/S Explores New Horizons with Peristeen Light Clinical Study
Coloplast A/S Explores New Horizons with Peristeen Light Clinical Study
Coloplast A/S (($GB:0QBO)) announced an update on their ongoing clinical study. Study Overview: Coloplast A/S is launching an...
1d ago
0QBO
Kamada Ltd’s Promising Phase III Trial: A Potential Game-Changer for Alpha-1 Antitrypsin Deficiency
Kamada Ltd’s Promising Phase III Trial: A Potential Game-Changer for Alpha-1 Antitrypsin Deficiency
Kamada Ltd (($KMDA)) announced an update on their ongoing clinical study. Study Overview: Kamada Ltd is conducting a...
1d ago
KMDA
AstraZeneca’s New Study on Opemalirsen: Potential Game-Changer for Renal Impairment Treatment?
AstraZeneca’s New Study on Opemalirsen: Potential Game-Changer for Renal Impairment Treatment?
AstraZeneca (($AZN)) announced an update on their ongoing clinical study. AstraZeneca has initiated a Phase I clinical study...
1d ago
AZN
AbbVie’s ABBV-277 Study: A New Frontier in Drug Safety Evaluation
AbbVie’s ABBV-277 Study: A New Frontier in Drug Safety Evaluation
Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie is currently conducting a clinical study titled...
1d ago
ABBV